Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis

Vasey, Frank B.; Germain, Bernard F.; Espinoza, Luis R.; Box, Patrick; Bockow, Barry; Lipani, John A.; Mullen, Bernard J.; Brodsky, Alan L.; Fleischmann, Roy; Fogari, Robert; Keller, Michael I.; Partridge, Raymond E. H.

doi:10.1016/0002-9343(87)90595-x

Cited by 19 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Forty good-or fair-quality placebo-controlled trials (in 50 publications) 33,[36][37][38]43,[54][55][56][64][65][66][68][69][70][71]73,[75][76][77][79][80][81][83][84][85][86]88,93,94,98,100,109,110,[153][154][155][156][157]177,196,[198][199][200][201][202][203][204][205]208,209 involving 13,943 patients meeting inclusion criteria evaluated antidepressants to treat chronic pain; 32 were short-term studies, 5 intermediate-term, 79,84,86,93,204 and 3 long...…”

Section: Detailed Assessmentmentioning

confidence: 99%

Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report 1

Selph¹,

McDonagh²,

Pappas³

et al. 2022

View full text Add to dashboard Cite

Purpose of ReviewEvaluate the benefits and harms of nonopioid drugs in randomized controlled trials of patients with specific types of chronic pain, considering the effects on pain, function, quality of life, and adverse events. Key Messages• In the short term, improvement in pain and function was small with specific anticonvulsants, moderate with specific antidepressants in diabetic peripheral neuropathy/post-herpetic neuralgia and fibromyalgia, and small with nonsteroidal antiinflammatory drugs (NSAIDs) in osteoarthritis and inflammatory arthritis. • In the intermediate term, evidence was limited, with evidence of benefit for memantine in fibromyalgia and for serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants in low back pain and fibromyalgia. • In the long term, evidence was too limited to draw conclusions. In general, evidence on quality of life was limited and no treatment achieved a large improvement in pain or function.• Small to moderate, dose-dependent increases in withdrawal due to adverse events were found with SNRIs duloxetine and milnacipran, anticonvulsants pregabalin and gabapentin, and NSAIDs. Large increases were seen with oxcarbazepine. NSAIDs have increased risk of serious gastrointestinal, liver dysfunction, and cardiovascular adverse events.

show abstract

Section: Detailed Assessmentmentioning

confidence: 99%

Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report 1

Selph¹,

McDonagh²,

Pappas³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Gibofsky et al (2007) [44] and Zhao et al (2000) [55], even though reported adverse events, did not evaluate other important outcomes (such as improvement of pain, swelling and duration of morning stiffness), and thus showed reporting bias. Also, two other clinical trials which described disease diagnostic did not cite the criteria used [56,57].…”

Section: Plos Onementioning

confidence: 99%

“…Hypertension [40,42,44] and headache [40,44,49,[57][58][59] were commonly reported adverse events. No study reported serious adverse events leading to death or hospitalization.…”

Section: Plos Onementioning

confidence: 99%

Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis

et al. 2021

View full text Add to dashboard Cite

Evidence on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticoids for rheumatoid arthritis (RA) is inconclusive and is not up to date. This systematic review assessed the effectiveness and safety of these anti-inflammatories (AI) in the treatment of RA. COCHRANE (CENTRAL), MEDLINE, EMBASE, CINAHL, Web of Science and Virtual Health Library were searched to identify randomized controlled trials (RCT) with adults which used AI (dose represented in mg/day) compared with placebo or active controls and was carried out up to December of 2019. Reviewers, in pairs and independently, selected studies, performed the data extraction and assessed the risk of bias. The quality of the evidence was assessed by GRADE. Network meta-analyses were performed using the Stata v.14.2. Twenty-six articles were selected (NSAIDs = 21 and corticoids = 5). Naproxen 1,000 improved physical function, reduced pain and the number of painful joints compared to placebo. Etoricoxib 90 reduced the number of painful joints compared to placebo. Naproxen 750 reduced the number of swollen joints, except for etoricoxib 90. Naproxen 1,000, etoricoxib 90 and diclofenac 150 were better than placebo regarding patient assessment. Assessment physician showed that NSAIDs were better than placebo. Meta-analyses were not performed for prednisolone and prednisone. Naproxen 1,000 was the most effective drug and celecoxib 200 showed fewer adverse events. However, the low quality of the evidence observed for the outcomes with NSAIDs, the absence of meta-analyses to assess the outcomes with corticoids, as well as the risk of bias observed, indicate that future RCT can confirm such findings.

show abstract

“…La eficacia ele la Nabumetona en e l tratamiento de la osteoartritis ha sic.lo puesta ele manifiesto e n varios estudios comparativos (Tabla ll) (37)(38)(39)(40)(41)(42)(43)(44)(45)(46). Nabumetona 1 g/clía produce una respuesta sintomática similar a ácido-acetil-salicílico 900 mg/4 veces al día, Diclofe nac 50 mg/ 3veces/ día, !buprofen, 400 mg/4veces/día, Indometacina 25 mg/3 veces/ día y Naproxen 250 mg/2veces/c.lía.…”

Section: Os Teoa1•trwsunclassified

Nabumetona

Simon

Sádaba

Honorato

2017

revista-de-medicina

View full text Add to dashboard Cite

Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis

Cited by 19 publications

References 0 publications

Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report 1

Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report 1

Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis

Nabumetona

Contact Info

Product

Resources

About